StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Eye Care Portfolio [folded into All Other in Q1 2026] by Year

Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide reported growth YoY (%) (%)

AbbVie Eye Care Portfolio [folded into All Other in Q1 2026]: -5.9% in FY2025, up 1.3 pts from a year earlier.

Latest, FY2025
-5.9%
Period ended Dec 31, 2025
Change on a year earlier
+1.3 pts
-7.2% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below

Where the FY2025 figure comes from

“|| Eye Care | 954 | 1,155 | 2,109 | (10.2) | (2.0) | (5.9) | (1.2) | (5.5)”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEye Care Portfolio [folded into All Other in Q1 2026] — Worldwide reported growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 2025-5.9%+1.3 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
FY2024Dec 31, 2024-7.2%+3.4 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
FY2023Dec 31, 2023-10.6%+13.7 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
FY2022Dec 31, 2022-24.3%-87.6 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
FY2021Dec 31, 202163.3%–Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗

Cite this data

StockData. (2026). AbbVie Eye Care Portfolio [folded into All Other in Q1 2026] (%), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-eye-ww-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.